作者
Fan Xia,Yaqi Wang,Hui Wang,Lijun Shen,Zuo‐Lin Xiang,Yutian Zhao,Huo-Jun Zhang,Juefeng Wan,Hui Zhang,Yan Wang,Ruiyan Wu,Jingwen Wang,Yang Wang,Mengqian Zhou,Shujuan Zhou,Yajie Chen,Zhiyuan Zhang,Xian Wu,Yan Xuan,Renjie Wang,Yiqun Sun,Tong Tong,Xun Zhang,Lei Wang,Dan Huang,Weiqi Sheng,Hao Yan,Yang Xu,Yuxin Shen,Yu Xu,Ruping Zhao,Miao Mo,Guoxiang Cai,Sanjun Cai,Ye Xu,Zhen Zhang
摘要
To assess whether the integration of PD-1 inhibitor with total neoadjuvant therapy (iTNT) can lead to an improvement in complete responses (CRs) and favors a watch-and-wait (WW) strategy in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS) locally advanced rectal cancer (LARC).